Skip to Content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    Two Alzheimer’s Updates (Lilly and TauRx)

    When you look at the stock charts of the major pharma companies, there’s not a lot of excitement to be had. Until you get to Eli Lilly, that is. Over the last year, the S&P 500 is up about 5%, and most of the big drug stocks are actually negative (Merck -0.4%, Sanofi down 6%… Read More
  • Alzheimer's Disease

    More on Axovant’s IPO

    Update: the IPO went off at the top of its range, I am sorry to report. More here from FierceBiotech, and I agree with John Carroll’s take. I wrote just recently about Axovant and their plans to go public with an Alzheimer’s therapy picked up on the cheap from GSK. Now here’s a look from… Read More
  • Alzheimer's Disease

    An Alzheimer’s IPO, Because Why Not

    Now here’s someone with optimism to burn, compost, and scatter to the winds. According to FierceBiotech, Vivek Ramaswamy has started a company called Axovant Pharmaceuticals, and their asset is a 5-HT6 antagonist from GSK. It goes back to the SmithKline days, when it was known as SB742457. It was in development for Alzheimer’s, apparent… Read More
  • Alzheimer's Disease

    Sulfur, Sulfur, Sulfur

    Does anyone know of any phosphatase inhibitors that aren’t hideous? I ask this because someone sent along a question about this paper, from last August, that I’d missed at the time (press release here, but the paper’s open-access as well). Here’s a commentary in the journal itself. It’s work from Yale on an enzyme call… Read More
  • Alzheimer's Disease

    Another Argument For Tau

    Just to give most everyone in the Alzheimer’s field a little more reason to doubt themselves, the Mayo Clinic has published a study suggesting that the pathology associated with tau protein (neurofibrillary tangles, NFT) is (as some have always maintained) more important than that associated with beta-amyloid. Our observations reaffirm the co… Read More
  • Alzheimer's Disease

    Biogen’s Alzheimer’s Data

    If you’re a rabid biotech investor, you already know all about Biogen’s data this morning. If you’re sane, or insane in some other, more interesting direction, then here’s what’s up: last December, the company released some Phase I data suggesting that their amyloid antibody, BIIB037 (aducanumab) was showing better-tha… Read More
  • Alzheimer's Disease

    Gamma-Secretase Inhibitors: The Wrong Way Around?

    Here’s an Alzheimer’s mystery, and that area was not lacking for them before. A paper in Neuron from Harvard/Mass General/Brigham & Women’s says that we may have been thinking about gamma-secretase the wrong way around. (Here’s a press release from Harvard, although I believe the paper is open-access as well). That enzy… Read More
  • Alzheimer's Disease

    New Alzheimer’s Research in the UK

    Oxford University’s new Drug Discovery Institute is making a big push in dementia and Alzheimer’s. Update: link fixed, I hope. One one level, that’s good news, because this is a tough area that needs all the well-placed shots that can be aimed at it. The folks Oxford will be staffing this institute with will surely… Read More
  • Alzheimer's Disease

    “From All This You’d Imagine, That There Must Be Something Learned. . .”

    Eli Lilly’s phase III clinical trial of semagacestat, a gamma-secretase inhibitor, was a notable disaster. The drug did absolutely nothing at all for Alzheimer’s patients – in fact, if anything, it made them slightly worse. The amyloid hypothesis was not illuminated in any useful way by this work – in fact, if anything, the… Read More
  • Alzheimer's Disease

    Another Alzheimer’s Antibody Goes Down

    The clinical failure rate for disease-modifying Alzheimer’s therapies remains perfect, unfortunately: a flat 100%. The latest news is from Roche. Their in-licensed amyloid-targeting antibody (gantenerumab, from MorphoSys) came up empty on an interim trial analysis. Other trials are apparently continuing, but with what hopes? Roche’s rat… Read More
...456...